Cardiogenic shock accounts for~ 100,000 annual hospital admissions in the United States.
Despite improvements in medical management strategies, in-hospital mortality remains …

Cardiogenic shock is a critical condition of low cardiac output resulting in insufficient
systemic perfusion and end-organ dysfunction. Though significant advances have been …

These guidelines for adult and pediatric anticoagulation for extracorporeal membrane
oxygenation are intended for educational use to build the knowledge of physicians and …

Lung transplantation can potentially be a life-saving treatment for patients with nonresolving
COVID-19–associated respiratory failure. Concerns limiting lung transplantation include …

Background Venoarterial extracorporeal membrane oxygenation (va-ECMO) is an advanced
life support for critically ill patients with refractory cardiogenic shock. This temporary support …

Anticoagulation of patients supported by extracorporeal membrane oxygenation is
challenging because of a high risk of both bleeding and thrombotic complications, and often …

Cardiogenic shock remains a major cause of morbidity and mortality for patients with acute
myocardial infarction and advanced heart failure. Intra-aortic balloon pump has been the …

Cardiovascular disease is the leading cause of death worldwide. Blood‐contacting medical
devices provide critical support for patients with severe respiratory and/or cardiac failure …

Background: Bivalirudin is a direct thrombin inhibitor (DTI) that can be an alternative to
unfractionated heparin (UFH). The efficacy and safety of bivalirudin in anticoagulation …

Extracorporeal membrane oxygenation (ECMO) was first started for humans in early 1970s
by Robert Bartlett. Since its inception, there have been numerous challenges with …